Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer

NCT02182050 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: BIBF 1120 ES low dose
DRUG: BIBF 1120 ES high dose
DRUG: Placebo to BIBF 1120 ES

Sponsor

Boehringer Ingelheim